FDA Proposes Rules for Generative AI Medical Devices

The U.S. Food and Drug Administration (FDA) issued a discussion paper on August 18, 2026, targeting generative AI medical devices ^[1][2]. The agency is seeking public feedback on a new regulatory framework to manage these evolving technologies ^[1]. This move aims to foster innovation while maintaining high standards for patient safety in healthcare ^[2][3].

The FDA is exploring competency-based evaluations for AI-enabled tools ^[1]. The framework also suggests risk-proportionate monitoring once devices are on the market ^[1][3]. Experts believe these updates are necessary because traditional regulatory paths may not fit the fast pace of generative model development ^[3].